http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012505880-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-404 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 |
| filingDate | 2009-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-03-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012505880-A |
| titleOfInvention | New benzylidene-indolinone and its medical and diagnostic applications |
| abstract | The present invention relates generally to organic chemistry, biochemistry, pharmacology, and medicine. More specifically, the present invention is expected to have beneficial effects on diseases associated with abnormal PK activity by modulating the activity of protein kinases (“PKs”), particularly protein tyrosine kinases. It relates to indolin-2-one derivatives and their physiologically acceptable salts and prodrugs. The present invention is further directed to the use of these compounds alone or in combination with other therapeutic agents for the alleviation, prevention and / or treatment of protein kinase mediated diseases and disorders such as cancer. To do. |
| priorityDate | 2008-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 624.